Cubist to acquire Trius, Optimer

Cubist Pharmaceuticals (CBST) says it will acquire Trius Therapeutics (TSRX) for $13.50/ share plus CVRs worth $2/ share. (PR)

CBST will also buy Optimer Pharmaceuticals (OPTR) for $10.75/ share plus CVRs worth $5/ share tied to Dificid sales milestones. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs